Vascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation

dc.contributor.authorSalmi Marko
dc.contributor.authorJalkanen Sirpa
dc.contributor.organizationfi=MediCity|en=MediCity|
dc.contributor.organizationfi=biolääketieteen laitos|en=Institute of Biomedicine|
dc.contributor.organization-code1.2.246.10.2458963.20.77952289591
dc.contributor.organization-code1.2.246.10.2458963.20.83772236069
dc.converis.publication-id28550612
dc.converis.urlhttps://research.utu.fi/converis/portal/Publication/28550612
dc.date.accessioned2022-10-28T12:31:52Z
dc.date.available2022-10-28T12:31:52Z
dc.description.abstractSignificance: Vascular adhesion protein-1 (VAP-1) is an ectoenzyme that oxidates primary amines in a reaction producing also hydrogen peroxide. VAP-1 on the blood vessel endothelium regulates leukocyte extravasation from the blood into tissues under physiological and pathological conditions.<div><br /></div><div>Recent Advances: Inhibition of VAP-1 by neutralizing antibodies and by several novel small-molecule enzyme inhibitors interferes with leukocyte trafficking and alleviates inflammation in many experimental models. Targeting of VAP-1 also shows beneficial effects in several other diseases, such as ischemia/reperfusion, fibrosis, and cancer. Moreover, soluble VAP-1 levels may serve as a new prognostic biomarker in selected diseases.</div><div><br /></div><div>Critical Issues: Understanding the contribution of the enzyme activity-independent and enzyme activity-dependent functions, which often appear to be mediated by the hydrogen peroxide production, in the VAP-1 biology will be crucial. Similarly, there is a pressing need to understand which of the VAP-1 functions are regulated through the modulation of leukocyte trafficking, and what is the role of VAP-1 synthesized in adipose and smooth muscle cells.</div><div><br /></div><div>Future Directions: The specificity and selectivity of new VAP-1 inhibitors, and their value in animal models under therapeutic settings need to be addressed. Results from several programs studying the therapeutic potential of VAP-1 inhibition, which now are in clinical trials, will reveal the relevance of this amine oxidase in humans.</div>
dc.format.pagerange314
dc.format.pagerange332
dc.identifier.jour-issn1523-0864
dc.identifier.olddbid177080
dc.identifier.oldhandle10024/160174
dc.identifier.urihttps://www.utupub.fi/handle/11111/32907
dc.identifier.urnURN:NBN:fi-fe2021042717978
dc.language.isoen
dc.okm.affiliatedauthorSalmi, Marko
dc.okm.affiliatedauthorJalkanen, Sirpa
dc.okm.discipline3111 Biomedicineen_GB
dc.okm.discipline3111 Biolääketieteetfi_FI
dc.okm.internationalcopublicationnot an international co-publication
dc.okm.internationalityInternational publication
dc.okm.typeA2 Scientific Article
dc.publisherMARY ANN LIEBERT, INC
dc.publisher.countryUnited Statesen_GB
dc.publisher.countryYhdysvallat (USA)fi_FI
dc.publisher.country-codeUS
dc.relation.doi10.1089/ars.2017.7418
dc.relation.ispartofjournalAntioxidants and Redox Signaling
dc.relation.issue3
dc.relation.volume30
dc.source.identifierhttps://www.utupub.fi/handle/10024/160174
dc.titleVascular Adhesion Protein-1: A Cell Surface Amine Oxidase in Translation
dc.year.issued2019

Tiedostot

Näytetään 1 - 1 / 1
Ladataan...
Name:
ars.2017.7418.pdf
Size:
950.6 KB
Format:
Adobe Portable Document Format
Description:
Publisher's version